STOCK TITAN

Point72 discloses small PLRX (NASDAQ: PLRX) stake of 46,537 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Pliant Therapeutics, Inc. received an amended Schedule 13G/A from Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reporting a small ownership position. As of the close of business on December 31, 2025, the group beneficially owned 46,537 shares of common stock, representing 0.1% of the outstanding class.

The filing explains that the shares are held by an investment fund managed by Point72 Asset Management, with Point72 Capital Advisors as its general partner and Mr. Cohen controlling both entities. The filers state that the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026

FAQ

What ownership stake in PLRX does Point72 report in this 13G/A?

Point72 entities and Steven A. Cohen report a beneficial ownership of 46,537 shares of Pliant Therapeutics common stock, which represents 0.1% of the class as of December 31, 2025, indicating only a very small minority position.

Who are the reporting persons in the Pliant Therapeutics (PLRX) Schedule 13G/A?

The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons. Point72 Asset Management manages the fund holding the shares, Point72 Capital Advisors is its general partner, and Cohen controls both entities.

Does Point72 seek control of Pliant Therapeutics (PLRX) with this stake?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics, and are not held in connection with any transaction having that control-related purpose or effect.

How many PLRX shares does each Point72 reporting person control?

Each reporting person—Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen—reports 46,537 shares of Pliant Therapeutics with shared voting and dispositive power and no sole voting or dispositive power, reflecting the same underlying investment fund position.

What type of securities are covered in this Pliant Therapeutics (PLRX) 13G/A filing?

The filing covers common stock of Pliant Therapeutics, Inc., with a par value of $0.0001 per share, identified by CUSIP 729139105. All reported ownership relates to this single class of securities.

When did the ownership level triggering this PLRX Schedule 13G/A occur?

The date of the event requiring this statement is December 31, 2025. Ownership information, including the 46,537 shares and 0.1% of the class, is provided as of the close of business on that same date.
Pliant Therapeutics, Inc.

NASDAQ:PLRX

PLRX Rankings

PLRX Latest News

PLRX Latest SEC Filings

PLRX Stock Data

68.21M
61.45M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO